From single excipients to dual excipient platforms in dry powder inhaler products.
Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the 'dual excipient platform' has recently been achieved. This article provides an overview of the background and current status of the development of such 'dual excipient platform' based DPI products.
Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom.
Jagdeep
J
Shur
Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom. Electronic address: r.price@bath.ac.uk.
Robert
R
Price
Chiesi Ltd., Bath Road, Chippenham, Wiltshire, United Kingdom.
David
D
Lewis
Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.
Paul M
PM
Young
Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.
Grahame
G
Woollam
Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.
Dilraj
D
Singh
Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.
Stephen
S
Edge
D000280:Administration, Inhalation; D004339:Drug Compounding / Q000379:methods*; D058995:Dry Powder Inhalers / Q000379:methods*; D005079:Excipients / Q000737:chemistry*; D006801:Humans; D007785:Lactose / Q000737:chemistry*; D010316:Particle Size; D012138:Respiratory Therapy / Q000379:methods; D013229:Stearic Acids / Q000737:chemistry*; D013499:Surface Properties
D005079:Excipients; D013229:Stearic Acids; C031183:stearic acid; D007785:Lactose
Dry powder inhaler; Excipients; Formulation; Inhalation